Therapeutics
Gene Expression Silencing
RNA Interference (RNAi) Oligos for Targeted Therapy Development
Jump To:
Overview
RNAi is a powerful biological process that utilizes short, non-coding RNA molecules (miRNAs) to suppress gene expression through targeted neutralization or degradation of messenger RNA (mRNA).
Therapeutic development centered on the use of RNAi to silence or suppress gene activity requires the use of small RNA molecules with high specificity and stability to ensure potency, minimize off-target effects, and ensure efficient delivery into the cell.
Oligo Factory leverages finely-tuned solid phase synthetic chemistry to produce high-quality siRNA and miRNA from microgram to hundreds of grams quantities. Our NANDA Series synthesizers enable precise control and enhanced purity for even the most complex siRNA and miRNA sequences.
Discover how Oligo Factory leveraged our expertise in post-synthesis conjugation to enable a therapeutics developer to reduce costs and ensure stability through production of a siRNA-GalNAc conjugate in this case study. [include button for download case study] (I still need to update logo on it and send to you)
Features & Benefits
Use Cases
Pushing the Boundaries of Medicine
From investigational research to the development of novel therapies, our high-quality RNAi molecules support innovation.
- miRNA research for cancer therapeutics
- Development of siRNA-based drugs for genetic disorders
- Neurodegenerative disease studies
- Antiviral therapy development
- RNAi screens for drug target identification
- Functional genomics screening
